Genetically Engineered Cancer Mouse Model

  • Principle
  • Experimental Materials
  • Experimental Procedure
  • Troubleshooting

Materials Required

/

Principle

Genetically engineered cancer mouse models (GEMMs) enable in vivo tumor initiation by conditionally activating oncogenes or inactivating tumor suppressor genes in a tissue-specific and temporally controlled manner using Cre-loxP recombination systems, allowing modeling of endogenous tumor development within the native microenvironment. In the widely used conditional Kras model, a latent oncogenic Kras allele (LSL-Kras^G12D^) remains transcriptionally silenced until Cre recombinase excises a stop cassette, resulting in tissue-specific oncogene activation and subsequent tumor formation that recapitulates early tumor initiation and progression in vivo[1].

MCE has not independently verified the accuracy of these methods. They are for reference only.

Experimental Materials

• LSL-Kras(G12D^ transgenic mouse line: provides conditional oncogene activation system for tumor initiation in vivo[1].

• Adenovirus expressing Cre recombinase (Ad-Cre): used to activate conditional alleles in target tissues such as lung epithelium[1].

• Animal housing system for maintaining specific-pathogen-free transgenic mouse colonies for controlled tumor induction experiments[1].

• In vivo delivery system (e.g., intratracheal administration setup in lung models): enables localized delivery of Cre-expressing vectors to target tissue[1].

Experimental Procedure

• LSL-Kras^G12D^ mice are bred and maintained under controlled conditions until experimental induction age, ensuring the presence of conditional alleles prior to Cre-mediated recombination.
Experimental cohorts are prepared for somatic activation of oncogenic Kras through targeted delivery of Cre recombinase to the tissue of interest, typically the lung epithelium in established adenoviral delivery models[1].

• Adenovirus encoding Cre recombinase is administered to target tissues in LSL-Kras^G12D^ mice to induce recombination of the floxed stop cassette, resulting in activation of oncogenic Kras expression in infected cells.
Following recombination, mice are monitored longitudinally for tumor initiation and progression driven by endogenous oncogene expression in the relevant tissue compartment[1].

• Tumor formation is assessed as a consequence of spatially restricted recombination events induced by Cre delivery, enabling analysis of early lesion development in vivo[1]. Tumor development is evaluated in vivo following Cre-mediated activation of Kras^G12D^ by assessing the emergence and progression of lesions in the targeted tissue.
The model enables comparison between recombined and non-recombined tissue regions, serving as internal controls for Cre specificity and oncogene-driven transformation efficiency[1].

• Tumor burden and initiation frequency are interpreted as functional outputs of successful recombination and oncogene activation in vivo[1].

Troubleshooting

Problem: No tumor formation after Cre delivery

• Possible Cause: Inefficient Cre-mediated recombination or insufficient viral delivery to target tissue

• Literature-supported Solution: Ensure effective Cre delivery to the target lung epithelium, as tumor initiation depends on successful recombination of the LSL-Kras^G12D^ allele in infected cells[1].

Problem: Mosaic or localized tumor distribution

• Possible Cause: Patchy infection or uneven Cre recombinase expression in target tissue

• Literature-supported Solution: Tumor initiation occurs only in recombined cells, indicating that spatial distribution reflects localized Cre activity in vivo[1].

Share